TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?

• Riccardo Bomben,
• Antonella Zucchetto,
• Federico Pozzo,
• Erika Tissino,
• Tamara Bittolo,
• Jacopo Olivieri,
• Annalisa Chiarenza,
• Francesco Zaja,
• Maria Ilaria Del Principe,
• Davide Rossi,
• Valter Gattei

Affiliations

Riccardo Bomben

1 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy

Antonella Zucchetto

1 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy

Federico Pozzo

1 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy

Erika Tissino

1 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy

Tamara Bittolo

1 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy

Jacopo Olivieri

2 Clinica Ematologica, Centro Trapianti e Terapie Cellulari “Carlo Melzi” DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy

Annalisa Chiarenza

3 Division of Haematology, Ferrarotto Hospital, Catania, Italy

Francesco Zaja

4 Department of Medical, Surgical and Health Sciences, University of Trieste, Italy

Maria Ilaria Del Principe

5 Division of Haematology, University of Tor Vergata, Rome, Italy

Davide Rossi

6 Haematology, Institute of Oncology Research, Bellinzona, Switzerland

Valter Gattei

1 Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano (PN), Italy